Monday, 14 October 2019

Phebra continues international business expansion

24 May 2019 | News

Phebra establishes new subsidiary in Canada

image credit-

image credit-

Australian pharmaceutical firm Phebra has continued its international business expansion with the opening of its subsidiary in Montreal, Canada. The new entity, Phebra Canada, will be headed by Tony Romagnino, Vice President of Phebra's current North America operations.

Further, Phebra Canada has announced the marketing approval for Arsenic Trioxide Solution for Injection for Acute Promyelocytic Leukaemia (APL).

"Arsenic Trioxide (ATO) is recognised as a very effective treatment for newly diagnosed APL patients and we are extremely pleased to have received its marketing approval in Canada," Mr Romagnino said.

Chief Executive Officer, Dr Mal Eutick, welcomed the marketing approval for Arsenic Trioxide Solution for Injection in Canada and the UK, saying it was a good example of how the Company's international expansion strategy enhanced its ability to deliver new and existing critical care products into new markets.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Is Asia-Pacific dominating the global digital transformation in healthcare market?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls